Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.4936
-0.0123 (-2.43%)
Nov 17, 2026, 9:41 AM EST - Market open
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Tagmokitug’s early esophageal data showed 89% ORR in 9 patients, including 100% among PD-L1-positive patients, and the planned next step is an FDA discussion on second-line development. LOQTORZI sales were about $14 million for the quarter, with 2027 growth targets outlined.

Denny Lanfear
CEO, Coherus Oncology

Good morning. I'm Denny Lanfear, CEO of Coherus Oncology. It's my pleasure today to talk to you about our clinical programs, as well as LOQTORZI, our commercial asset. I want to first thank the organizers for inviting us to the conference this year and apprise you of our FLS and our forward-looking statements. Today, first of all, I'll talk a little bit about the corporate strategy and a summary of that. I'll spend the majority of my time, my remarks, with respect to tagmokitug, which is our T regulatory cell depleter and our recently completed clinical program of six different indications, which is very exciting, and our selection of esophageal cancer going forward. Then I'll talk a little bit about casdozokitug, which is our first-line HCC study for us. The investment thesis for the company is threefold.

First of all, a best-in-disease IO pipeline with tagmokitug across both first-line and second-line esophageal cancer, and both etiologies, both squamous and adeno. As I'll talk a little bit in a moment, this is some 400,000-500,000 patients globally and represents a substantial unmet medical need for patients. We have, I think, really just extraordinarily good clinical results that we have seen. LOQTORZI is our foundation PD1. It's approved and commercialized in nasopharyngeal cancer. I'll talk to you a little bit about that and how we're moving the market forward there, both in 2026 and 2027. Recently, we have right-sized the organization, having completed so many clinical trials, completed transition services agreements to support the divestiture of our biosimilar business, and then a few other things having to do with bringing our production of LOQTORZI into the U.S.

We're able to right-size our organization, reducing our headcount from about 140 to about 100 folks, reducing our quarterly burn $6 million-$7 million, and very importantly, reducing the hurdle rate where we need to do sales to reach our core cash burn down to about $25 million-$30 million from $30 million-$35 million per quarter. This is our pipeline. As you can see here in the middle with the tagmokitug in purple, there's a number of studies. I'll talk to you about this just in a little moment, but I think that we had a very comprehensive set of studies going across various indications. We still have one very interesting study, which you see here at the bottom, and that is in conjunction with our good friends at J&J for pasritamig, which is a T-cell engager. This is in prostate.

I don't have any slides on pasritamig for you today. We're starting that study. I think we're going to inject the first patient either this week or next week. What's very interesting about this is T-cell engagers require T-cells to engage with in the tumor microenvironment. If you successfully deplete the T regulatory cells, we have demonstrated remodeling of the tumor microenvironment and the ability for it to be infiltrated by fresh T-cells. We have selected esophageal cancer for follow-on development. I would just, regarding the first point here about we believe we have the right drug with the right target and focused on the right indication. Others have had a problem with T regulatory cell depletion. There's been deficits with pharmacology. This is actually a very difficult target. It's a GPCR receptor, I'll remind you.

That means there's a very small amount of real estate protruding from the surface of the receptor. Therefore, it's very difficult to get a highly selective antibody to address that. We feel we have a best-in-class antibody, which has shown very good safety, high selectivity, and I'll show you that safety data subsequently in the studies that we have done. I'll also show you, of course, our results in both first-line and second-line esophageal, which handily exceed standard of care. Then I'll talk a little bit further about the market size and how, really, this integrates well with our plans for global partnering this asset. One of the key issues that's very convenient for us as we look forward is the very high incidence of esophageal cancer, for example, in Asia. This, we feel, will allow us to find strong partners to help us.

As I indicated a moment ago, we conducted a strategic prioritization after completing all of these studies and right-sized our organization. This was facilitated by, of course, reducing the number of studies from seven, very much focused really on esophageal. Secondarily, though, it allowed us to focus the company and all the folks that were there really on just what we really need to do to get that done. As I said, we'd right-sized it down from about 142 to about 100 FTEs, really without impairing our functionality at all as we have really focused. I would just say since we've evolved out of the biosimilar business, we have continually refined the company and reduced the size of it. Lastly, one of the things we'll do is focus on getting to core burn break-even, and I talked about this just a second ago.

The hurdle right now here is down to $25 million-$30 million, which we feel we can handily get to next year. I just want to remind you of the action of when you overcome immune resistance and its benefit to patients. What you see here is the Kaplan-Meier curve actually for nasopharyngeal cancer for LOQTORZI. 64.8 months in combination with chemotherapy versus 33.7 months on chemo alone. Really a significant benefit. This shows you that the benefit to patients accrues at the far end of the curve. Early on in the first three, six, nine months where you see the initial scans and you see the initial ORR, you really don't see a breakout difference between immunotherapy and, for example, chemotherapy. But this really is what's important to patients. Survival is the approval endpoint in the United States, as you know.

Toripalimab is really an extraordinary molecule that's shown strong activity across indications, but particularly in esophageal cancer. I direct you to the left side of this, where you see two histograms demonstrating that it is equipotent with low PD-L1 and high PD-L1 in esophageal cancer on a background of chemotherapy, versus you see here's KEYTRUDA, KEYNOTE-590, where it is not. As a matter of fact, KEYTRUDA, OPDIVO, and TECENTRIQ all had their labels removed in the United States for low PD-L1 patients. Further to the point, this is approved in Europe with both low and high PD-L1 and doing very well. This is a very clinical meaningful difference, of course, as I just outlined, the six-year survival, and we've been able to translate that to the NCCN guidelines, where we are the only product that is in first position.

With respect to our commercial strategy then, we are growing the revenues steadily. We guided earlier this year to achieving $15 million per quarter. We feel quite confident we will do that next quarter. This quarter, we did about $14 million. We will hit somewhere around $30 million per quarter in one of the quarters in 2027, and that should get us to core burn break-even with the company. Then, ultimately, we see this market, which is about a $250 million overall market, that we should be able to do about $40+ million per quarter there. The drivers on that, first of all, are the survival data. Secondarily, the investments we made in getting the claims data, so we can go to the physicians and the institutions where the patients are.

Lastly, we also made some other investments in our field footprint of adding additional territories so we could actually go into our alert system and have faster follow-up on those patients. Let me talk a little bit now about the very exciting clinical results, tagmokitug. Let me first take a step back and remind you about Tregs. They have a fundamental role in mediating immune homeostasis. This is particularly of interest in the mucosal system, right? Everything from the mouth, the esophagus, gastric, all the way down to CRC. What this does then is that as it is invaded by pathogens and food and all these things, the T regulatory system really moderates on a very dynamic basis the immune response. What this means, though, is this is the way cancer basically hijacks this response, creates immune resistance, and then grows.

Therefore, we thought that this was the ideal place to pursue an evaluation, and we went after each of these cancers, head and neck with squamous, and then esophageal carcinoma, upper GI, and then all the way to CRC. Significantly here, we pursued esophageal both in the context of squamous and adeno etiologies. You see that here. This is some of our results. I will dive into this and show you the actual data in just a moment. But here is the first-line esophageal data that you see. What is really remarkable about this, in the PD-L1 high patients, we saw a 100% response rate. 100% response rate, which compares to about a 50% response rate of standard of care, which is basically a PD-1 and chemotherapy. With esophageal, we saw a 33% response rate confirmed and a 44% response rate unconfirmed.

This is really remarkable insofar as the standard of care for second-line esophageal for both etiologies is chemotherapy, 10% response rate. This is really strong data and puts us in a position really where we can focus on esophageal both first and second line with the FDA going forward, and I will tell you about how we are going to do that in just a moment. Here is the setup for our studies. The first-line study was 12 patients. Second study was 20 patients split between high and low dose, and I will show you the dose response data, which is also very, very clean in just a moment. Then lastly, gastric, 40 patients across gastric, the esophageal, and so forth, primarily adenocarcinoma patients. This is the waterfall for the first-line esophageal. Very, very compelling, as you can see. 75% confirmed overall response rate, 100% ORR.

This really, 100% of the patients here showed tumor shrinkage. Remarkably, there was also activity in PD-L1 low and also very, very strong activity. The enrollment's ongoing. I think we got 11 patients in so far. We have one more to go here. This is really very, very encouraging. What I really like about this is it really is highly consistent with what toripalimab has shown in the past with respect to its activity in esophageal, only far better. This is our complete response patient, 88% reduction in the target lesions at time of the response. This is a PD-L1 positive patient. In this patient, really, you can see the mass and the diminution of the mass at the follow-ups. Here, for example, you can see the duration, and this is really, really important. You see the patients going out.

Here's our complete response patient, and you can see the duration. I started the presentation by showing you the responses with toripalimab on a background of chemotherapy in nasopharyngeal cancer and that very long duration benefit to patients. You see the very same thing here. This is really indicative of what you want to get when you overcome immune resistance for the patients, right? You don't get this huge ORR usually right in the front, but you get this very nice duration, which has significant benefit. Let me switch gears now and talk about esophageal, and there's two etiologies here, squamous and adeno. We looked at each of them at two different doses here. You can see the upper in the green, we have the low dose, which is the 300 mgs. Down below in purple, you see the high dose, which is 700 mgs.

What's really striking about this is really the stellar dose response that you see with these patients. The other thing that happened here, of course, was again, the duration, 5.5 months with respect to the progression-free survival. That compares handily with the standard of care at chemo, which is 2.5-3.5 months. This really sets us up really nice for conversations with the FDA, and I'll talk to you in just a second about our plans to go forward with that. Here's the waterfall chart for these patients, and you can see, the thing that I would point out here also is we also did circulating tumor ctDNA levels, which tracked along very, very nicely with the overall waterfall and the overall response. With respect to that, you see here we have a 55.6% clinical benefit rate, which is really outstanding.

33% confirmed ORR and a 44% unconfirmed. We're waiting for these patients to continue. A lot of them are still on study. This actually compares quite well with standard of care, where the ORR is only about 10% for chemotherapy. This, I'll just stop for a moment. This is a very high unmet need for the patients. These patients, esophageal, they go through first line. On a good day, they'll get a PD-1 plus chemo, but then they end up in second line, and all you can get is chemo in second line. High unmet need. These patients, as you can see, progress very quickly. This is the reason why we think the FDA conversations will be very fruitful for us. Here's the safety profile. I put this slide in because a lot of folks have had problems with the safety profile with the Treg depletion.

We've actually, I think, doing pretty well here. I would just point out the first-line esophageal, the TRAEs leading to tagmo discontinuation, half those are really due to chemo. What we plan to do in the follow-on studies is change the chemotherapy out to get rid of that particular TAE. Let me just talk a little bit about tagmo and tori and how we intend to go forward with that, with respect to our future adventures with the FDA. First of all, this is the first place that we'll focus. You may ask, why not go first into first line? A number of things. First of all, this is very, very high unmet need. These patients are passing very, very quickly. We think that we can get in here with an accelerated approval strategy with the FDA and fast track and breakthrough.

Our plan here really is to go to the FDA with the data that we have and then have a conversation with them about the study design and what we can do, and I'll show you that on a subsequent slide. These patients, generally speaking, have failed a PD-1 and chemo. It's very important, I would make this key point, is what we have demonstrated in the second line study is that we can rescue the immune response of T cells in this patient population, and we can enhance the effect of immunotherapy otherwise in this population. The very, very high activity of LOQTORZI in this indication, which was borne out previously, has been borne out yet again.

Secondarily, this allows us really, I think, to be in a position with the FDA to have a conversation with them and how much we can do clinically with them and how fast with the approval. Following that, we intend to go into first line. As I indicated, first line is a PD-1 plus chemo. We intend to go with the triplet, PD-1 plus tagmo and chemo against PD-1 and chemo, there you see. This also has the opportunity for accelerated approval. Importantly though, we will be able to go after these patients irrespective of PD-L1 status, whereas the other PD-1s, of course, are constrained because they're not active in low PD-L1. This is quite important. Here's our proposed randomized study for the second line. These are all patients who will have progressed on a PD-1 and have seen chemotherapy in the first line.

There's various ways that we can randomize this study. We may randomize it one to one or two to one, depending on conversations with the FDA. We believe this should be a multi-regional clinical trial, and so one of the key things we're going to do is set up partnerships for this. I jumped over this a moment ago, and I'll come to it in the last slide, but one of the very good things about pursuing esophageal cancer is the fact that we think we'll be able to get to partnerships in various parts of the world, particularly Asia, Japan, Korea, China. This is a really, really high incidence, and actually, we've already initiated this partnership discussions, and we have some financial advisors working for us on that.

The primary endpoint, of course, here is going to be ORR, randomized, blinded with a committee, and then the standard secondary endpoints of progression-free survival, overall survival. We'll go head-to-head with the triplet versus the double, I should say, versus the physician's choice of chemotherapy. I think we're optimistic about that we'll be able to be successful with this study. Currently our team is putting together the package for this. Should get this filed by the end of the year. We'll include the waterfalls and the spider charts like you saw just previously and see how we do with the FDA on this one. Let me just double-click here on the partnerships for a moment and the size of this market. In the U.S., the adenocarcinoma is about 15,000 patients, and the squamous about 6,000. That's about 20,000 patients overall.

Our ambition is to be best in disease globally with this indication, given the unique activity of toripalimab and then combining it with tagmokitug for Treg depletion. First of all, that's very good. We'll be able to do these patients in the U.S. We have deep relationships, for example, in community oncology and other places where we think we can get to these patients readily. Also, the partners in the ex-U.S. territories will probably contribute a lot of the squamous, in particular, patients, as you can see here. All right, let me just now double-click for a moment on casdozokitug, our anti-IL-27 asset, which continues in the clinical trials. You may recall that casdozokitug is a first-in-class anti-IL-27. IL-27 is very, very interesting.

What it does in the context of liver cancer is it firstly upregulates all the checkpoints, LAG-3, PD-1, and so forth, detunes the immune response down, and then downregulates all these cytokines. You can see it here. What casdozokitug does is basically binds IL-27 and pulls it out, allowing the immune response to continue. This showed excellent results in the first study that you see on this slide. On the right panel, you see the spider chart, the very deep, durable response. This was casdozokitug in a background standard of care, atezo/bev. This was really outstanding data. What we did was go forward with this now and set up a follow-on study to understand how do we get casdozokitug approved. You see that here. We're doing a study with 72 patients. This completed enrollment, I think, in April or May of this year.

This is across low-dose casdozo plus toripalimab, high-dose casdozo plus toripalimab, plus toripalimab and bev alone. The study is moving along. The data is maturing. One of the key things that we're doing is we're looking at the circulating tumor DNA levels and how those are going down with the treatment. This data, I would say, is taking a little longer than we'd like. We want to get this out in the second half. We'll probably talk about this right in front of JP Morgan or at JP Morgan this year. We're going to, at that point, also be able to have all of the circulating tumor DNA level correlated with the response data, correlated with the IL-27 data. It's a bit of data to get together, which is basically what we're working on. The opportunity here is significant globally and in the United States.

Even if we enrich for IL-27, I think it will be quite good. Let me just stop there, and I will just have a moment for any questions you guys might have. First of all, we believe that tagmokitug, our Treg depleter, has performed very, very well. We did a very systematic evaluation across these various cancers. While some of them were very promising, such as head and neck and so forth, where we could have gone into HPV-positive, I think the esophageal data was just exemplary. There is not much you can say about 100% response rate. We really want to follow the data and go there. Casdozo, I think, is another very, very interesting molecule. It has got an unrelated mechanism of action to tagmokitug, and in that sense, really represents a diversification with the company's pipeline going forward. LOQTORZI is performing well in nasopharyngeal cancer.

We are the only available and approved product in the U.S. We have got a great strategy for getting to those patients. I did not talk about it too much, but there are two key drivers of the growth that we are going to lean in on in 2027 with respect to our market. First of all, there is still about 30% of those patients that are getting chemo alone. These patients are getting 33.5 months of life instead of 64.8, which is really a tragedy. We are leaning in on chemo. When we educate physicians and healthcare providers, they are very, very responsive when we show them the data. The other place where we are going is really against the off-label IO, which does not have data that supports it like we do.

That is another conversation you can have, and we are very, very active, particularly with the community oncology groups with that going forward. Lastly, of course, we have been very cognizant of our footprint and our costs. We have always controlled our costs extremely well. We have continued to reduce and focus our organization down. We really refocused the non-commercial part of our business recently. We really want to maintain commercial and drive the sales upward through 2027, get that $30 million per quarter later on. But we are right-sized, we brought in the savings, and now we are focused there. At that point, I am happy to take any questions that you may have on the company in our remaining time. Yes, sir.

Speaker 2

Hi. One question. You showed a lot of programs that I may not get right, but tagmo, one of the things, 100% ORR that you showed. You also mentioned ctDNA response that correlated with that one.

Denny Lanfear
CEO, Coherus Oncology

Yeah.

Speaker 2

You didn't show any ctDNA data, but the response was like 100% clearance of ctDNA, or what percentage clearance of ctDNA?

Denny Lanfear
CEO, Coherus Oncology

Yeah.

Speaker 2

Or what was your data?

Denny Lanfear
CEO, Coherus Oncology

Yeah, I have Dr. Rosh Dias , he's my Chief Medical Officer here. Rosh, do you want to talk about that?

Rosh Dias
Chief Medical Officer, Coherus Oncology

Yeah. Hi. Thank you for the question. Two things I'll say. The overall response rate is 75%.

Speaker 2

Right.

Rosh Dias
Chief Medical Officer, Coherus Oncology

Actually, since the data cut from October 14th, we had a couple of additional ones as well. So it went from six out of eight, 75%, to eight out of nine, 89%. The 100% ORR was for PD-L1 positive patients.

Speaker 2

Right.

Rosh Dias
Chief Medical Officer, Coherus Oncology

The reason that that's important is because all of the approved PD-1s are only approved in PD-L1 positive, and those were the ORR metrics that Denny mentioned, with the benchmarks of around 50%. So we had 100%. If you look at the slide on the bottom of that panel on the left, you see some of the ctDNA data. The ctDNA, we don't have ctDNA for all patients, but what you do see is baseline and a decrease at some of the, for many of the patients that we have ctDNA, they correlated pretty nicely in terms of the decline with the patients who had a response, either partial response or complete response.

Speaker 2

Decline, but not complete clearance of ctDNA?

Rosh Dias
Chief Medical Officer, Coherus Oncology

Not complete disappearance, yeah. I think there was one patient who may have had complete disappearance, but this is still interim data.

Speaker 2

Right.

Rosh Dias
Chief Medical Officer, Coherus Oncology

We continue to follow these patients on.

Denny Lanfear
CEO, Coherus Oncology

But directionally, it's all very consistent. Yeah.

Speaker 2

ctDNA is everybody's following the patient.

Rosh Dias
Chief Medical Officer, Coherus Oncology

Exactly.

Denny Lanfear
CEO, Coherus Oncology

Yeah.

Rosh Dias
Chief Medical Officer, Coherus Oncology

It's essentially a molecular response, right?

Denny Lanfear
CEO, Coherus Oncology

Excellent.

Speaker 2

Thank you.

Denny Lanfear
CEO, Coherus Oncology

Excellent. Thank you all very much.